epirubicin

Epirubicin (4'-Epidoxorubicin), a semisynthetic L-arabino derivative of doxorubicin, serves as an antineoplastic agent primarily by inhibiting Topoisomerase, thereby impeding DNA and RNA synthesis. Additionally, it functions as a Forkhead box protein p3 (Foxp3) inhibitor, curbing regulatory T cell activity.

Epirubicin hydrochloride (Pharmorubicin) is an antineoplastic agent which can inhibit Topoisomerase.

NR-160 is an inhibitor of histone deacetylase 6 (HDAC6; IC50= 0.03 μM).1It is selective for HDAC6 over HDAC1, -2, -3, -4, and -8 (IC50s = 5.18, 2.26, 8.48, 55.4, and 14.7 μM, respectively). NR-160 is cytotoxic against a panel of seven cancer cell lines (IC50s = 22.5-51.8 μM). It enhances cytotoxicity induced by bortezomib in HL-60 cells, as well as cytotoxicity induced by epirubicin or daunorubicin in CCRF-HSB-2 T cell acute lymphoblastic leukemia cells.